CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
about
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.Novel biotechnology approaches in colorectal cancer diagnosis and therapy.A novel bispecific antibody, BiSS, with potent anti-cancer activities.An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors.BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.Recent advances of bispecific antibodies in solid tumors.Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigenRecombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent mannerMolecular Imaging of Radiolabeled Bispecific T-Cell Engager Zr-AMG211 Targeting CEA-Positive Tumors
P2860
Q34548319-9283A236-79EC-48B7-B9F9-FE0EB8CB1BF8Q37741534-1D91768B-E255-46E5-A18D-4D55B36963D2Q38728592-C79BE029-B430-4056-9D18-468632B52E12Q38788557-F8A3665C-8D4C-4B3B-9057-41811E5F1289Q39151211-1CB28F86-AE6A-421F-9CA0-80E0782153C4Q40038526-33FE9984-9DD7-4FF5-B7A9-CDAC46752293Q41252003-EF643228-0146-4A8D-AFD3-6FCA0507EC0CQ41302727-301A31A3-1447-4472-BCBB-424B908FFE0BQ41696278-BDC8999A-ED69-4AEF-88ED-0C9269DF0EE0Q41719908-908009E2-8F4B-416D-B388-1A810CD84AF5Q42060421-C48DB8D2-82BD-40B6-A153-E26EB78E4918Q42660142-FFCD9A8E-1D7D-408E-AA99-4831551E02D6Q47570404-669C88A2-0FDA-42DF-9E4E-91A977B38027Q48193189-6182400D-7154-4340-BD64-BCDCE4CC7180Q55362101-FFBF2A5D-08D1-443E-894E-D8D350EE1433Q56119780-3500425F-A439-4E06-A5CB-B12C886E320DQ57462228-ECA1F126-93BD-4000-9048-658476FA22DB
P2860
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
CEA/CD3 bispecific antibody ME ...... in colorectal adenocarcinomas
@ast
CEA/CD3 bispecific antibody ME ...... in colorectal adenocarcinomas
@en
type
label
CEA/CD3 bispecific antibody ME ...... in colorectal adenocarcinomas
@ast
CEA/CD3 bispecific antibody ME ...... in colorectal adenocarcinomas
@en
prefLabel
CEA/CD3 bispecific antibody ME ...... in colorectal adenocarcinomas
@ast
CEA/CD3 bispecific antibody ME ...... in colorectal adenocarcinomas
@en
P2093
P2860
P1476
CEA/CD3 bispecific antibody ME ...... in colorectal adenocarcinomas
@en
P2093
Kathy Mulgrew
Laura Richman
Lily Cheng
Maria Amann
Michael D Oberst
Patrick A Baeuerle
Petra Lutterbuese
Scott A Hammond
Stacy Fuhrmann
Steve Coats
P2860
P304
P356
10.4161/19420862.2014.975660
P577
2014-01-01T00:00:00Z